Yes I agree on the long term CSL will do well with $1B R&D budget. But on the short term with this uncertainty on their revenue, I doubt investors will be paying high PE multiple. CSL will have to demonstrate some visible potential products which are almost ready for the market or Vifor & Vaccine business come up with compensating increase in revenue. I think that is there issue at the moment.
Yes I agree on the long term CSL will do well with $1B R&D...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.90 |
Change
0.040(0.01%) |
Mkt cap ! $148.7B | |||
| Open | High | Low | Value | Volume |
| $307.95 | $308.24 | $306.26 | $42.01M | 136.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 97 | $307.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.90 | 3 | 1 |
View Market Depth
| Last trade - 11.36am 17/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |